The European Technology Platform for Nanomedicine (ETPN) and the EU-funded project ENATRANS, announce the launching of the 3rd edition of the Nanomedicine Award, which aim to promote and reward two excellent innovative nanomedicine-based solutions that could bring significant benefits to patients, answering thereby unmet medical needs. The winners in 2 categories will be announced and rewarded during the BIO-Europe conference in Berlin in November 2017. Apply Now!

Open to companies as well as to academic and private researchers across the globe, candidates should: - present totally new approaches based on Nanomedicine for the diagnosis and/or therapy of human diseases - describe explicit and defined potential market.

Applications will be assessed by a panel of highly-qualified nanomedicine, pharma, medtech and investment specialists.

The Award ceremony will take place during BIO-Europe 2017 in Berlin (Germany), on 7 November 2017.

Both winners will benefit from a full registration to BIO-Europe 2017 including the participation in the partnering event and a public presentation of the awarded projects. In addition, they will be granted an individual session with the experts of the Translation Advisory Board (TAB, http://www.nanomedtab.eu), a presentation slot during the ETPN Annual Event 2018 as well as a 1-year free membership to the ETPN (www.etpnanomedicine.eu).

The Award is supported by the EBD Group, the leading partnering firm for the global life science industry, and Nanobiotix, a late clinical-stage nanomedicine company pioneering novel approaches for the treatment of cancer.

THE DEADLINE TO SUBMIT CANDIDATURES IS 15 AUGUST 2017. APPLY ONLINE AT http://nanomedicine-award.com/apply-now/

Read more:
Nanomedicine Award 2017: applications are now open! - Cordis News